J&J vaccine and thrombosis: EU begins check

The EMA will check reports that those vaccinated against the coronavirus with the J&J drug in the United States have experienced side effects.

The European Medicines Agency (EMA) will check information about possible severe side effects of the Johnson & Johnson vaccine before the drug is actually used in the European Union. This was reported by the EMA on Friday, April 9.

As specified in the agency’s message, we are talking about the occurrence of thrombosis after vaccination. The vaccine of the American pharmaceutical company Johnson & Johnson was approved by the European Commission for use in the EU in March this year.

Reports of side effects from J&J in the US

Earlier, on April 8, it was reported that in the US state of North Carolina, the vaccination center against COVID-19 was temporarily closed after several people showed side effects after being vaccinated with the J&J vaccine. A day earlier, the same measures were followed in the state of Denver, where patients after vaccination with this drug complained of dizziness and nausea.

J&J Vaccine Benefits

Unlike most other vaccines, the J&J vaccine only needs to be given once, so more people can get access to the vaccine. In addition, the J&J vaccine does not require ultra-low temperatures to be stored and transported. Like the AstraZeneca and Sputnik V vaccines, J&J is a vector vaccine.

The U.S. Food and Drug Administration (FDA) registered the J&J vaccine in February 2021. The results of phase 3 clinical trials indicate that this drug reduces the risk of moderate to severe coronavirus by 66% after four weeks of vaccination.

Leave a Reply

Your email address will not be published. Required fields are marked *